Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer.

Feng X, Li H, Kornaga EN, Dean M, Lees-Miller SP, Riabowol K, Magliocco AM, Morris D, Watson PH, Enwere EK, Bebb G, Paterson A.

Oncotarget. 2016 Dec 27;7(52):85798-85812. doi: 10.18632/oncotarget.12622.

2.

Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer.

Feng X, Li H, Dean M, Wilson HE, Kornaga E, Enwere EK, Tang P, Paterson A, Lees-Miller SP, Magliocco AM, Bebb G.

Breast Cancer Res. 2015 May 3;17:65. doi: 10.1186/s13058-015-0575-2.

3.

Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.

4.

The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women.

Kim J, Han W, Jung SY, Park YH, Moon HG, Ahn SK, Lee JW, Kim MK, Kim JJ, Lee ES, You TK, Kang HS, Lee ES, Ro J, Lee JE, Nam SJ, Yim YH, Park IA, Noh DY.

Ann Surg Oncol. 2015 Oct;22(11):3481-8. doi: 10.1245/s10434-015-4399-1. Epub 2015 Feb 5.

PMID:
25652052
5.

Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.

Feeley LP, Mulligan AM, Pinnaduwage D, Bull SB, Andrulis IL.

Mod Pathol. 2014 Apr;27(4):554-61. doi: 10.1038/modpathol.2013.153. Epub 2013 Sep 20.

6.

Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.

Niikura N, Masuda S, Kumaki N, Xiaoyan T, Terada M, Terao M, Iwamoto T, Oshitanai R, Morioka T, Tuda B, Okamura T, Saito Y, Suzuki Y, Tokuda Y.

Clin Breast Cancer. 2014 Oct;14(5):323-329.e3. doi: 10.1016/j.clbc.2013.12.013. Epub 2013 Dec 30.

PMID:
24492237
7.

The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.

Thakur SS, Li H, Chan AMY, Tudor R, Bigras G, Morris D, Enwere EK, Yang H.

PLoS One. 2018 Jan 5;13(1):e0188983. doi: 10.1371/journal.pone.0188983. eCollection 2018.

8.

Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer.

Sutepvarnon A, Warnnissorn M, Srimuninnimit V.

J Med Assoc Thai. 2013 Feb;96 Suppl 2:S60-6.

PMID:
23590023
9.

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.

10.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

11.

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell'Orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou C.

JAMA Oncol. 2016 Feb;2(2):217-24. doi: 10.1001/jamaoncol.2015.4377.

PMID:
26633571
12.

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH.

Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.

PMID:
22495453
13.
14.

Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy.

Selz J, Stevens D, Jouanneau L, Labib A, Le Scodan R.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1123-32. doi: 10.1016/j.ijrobp.2012.02.047. Epub 2012 May 8.

PMID:
22572073
15.

Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.

Falck AK, Bendahl PO, Chebil G, Olsson H, Fernö M, Rydén L.

Breast Cancer Res Treat. 2013 Jul;140(1):93-104. doi: 10.1007/s10549-013-2617-8. Epub 2013 Jun 27.

PMID:
23807420
16.

Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.

Zhao S, Xu L, Liu W, Lv C, Zhang K, Gao H, Wang J, Ma R.

Int J Clin Exp Pathol. 2015 May 1;8(5):5744-8. eCollection 2015.

17.

Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.

Shandiz FH, Shabahang H, Afzaljavan F, Sharifi N, Tavasoli A, Afzalaghaee M, Roshanzamir E, Pasdar A.

Asian Pac J Cancer Prev. 2016;17(3):1347-50.

18.

Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer.

Kilickap S, Kaya Y, Yucel B, Tuncer E, Babacan NA, Elagoz S.

Asian Pac J Cancer Prev. 2014;15(3):1381-5.

20.

Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients.

Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, Mujtuba S, Malik B, Faridi N.

Asian Pac J Cancer Prev. 2013;14(7):4353-8.

Supplemental Content

Support Center